Increasing the radiation dose ups freedom of biochemistry fail ;
(HealthDay) for patients with prostate cancer (CaP) cancer, increasing the biologically equivalent dose (BED) of external beam radiation therapy (RT) is associated with the absence of biochemical failure (FFBF), but not with the improvement in overall survival (OS), distant metastasis (DM), or cancer-specific mortality (CSM), a study published online March 24 in the American Journal of Clinical Oncology .
Nicholas G. Zaorsky, M.D., of Fox Chase Cancer Center in Boston, and colleagues conducted a meta-analysis of 12 randomized controlled trials of external beam RT related to 6,884 patients with CaP. It is estimated that the linear relationships between the bed and percentages observed the results of five and 10 years. An application involving a subgroup analysis of three-dimensional shaped RT (3D-CRT) versus intensity modulated RT (IMRT) was performed to toxicities .
The researchers found that improving FFBF was seen with increasing BED, with 10 years of absolute improvements of 9.6 and 7.2 percent for patients with low and intermediate risk, respectively (P patients, despite treatment more BED.
“BED climbing RT has resulted in a significant improvement in the CP FFBF up to 10 years, but not with improvement in OS, DM, or CSM,” the authors write. “Therefore, FFBF is a poor substitute for the overall results of RT patients for testing.”
This article was originally published on medicalxpress, Read the original article
Posted in: Cancer